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Background: Post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most
common and most severe complication associated with diagnostic and therapeutic ERCP. A multivariate analysis of
risk factors for PEP is essential for identifying patients at high risk and subsequently choosing other suitable
diagnoses.
Methods: Pertinent publications were identified through systematic searches of MEDLINE, Elsevier, and Springer; we
performed a systematic review of 12 clinical studies published in the past ten years, selected out of 451 reviewed
articles, in which risk factors for pancreatitis were identified. Seven probable risk factors were evaluated, and
outcomes expressed in the case of dichotomous variables, as an odds ratio (OR) (with a 95% confidence interval,
95% CI).
Results: When the risk factors were analyzed, the OR for female gender was 1.40 (95% CI 1.24 to 1.58); the OR for
previous PEP was 3.23 (95% CI 2.48 to 4.22); the OR for previous pancreatitis was 2.00 (95% CI 1.72 to 2.33); the OR for
endoscopic sphincterotomy was 1.42 (95% CI 1.14 to 1.78); the OR for precut sphincterotomy was 2.11 (95% CI 1.72 to
2.59); the OR for Sphincter of Oddi dysfunction was 4.37 (95% CI 3.75 to 5.09); and the OR for non-prophylactic
pancreatic duct stent was 2.10 (95% CI 1.63 to 2.69).
Conclusions: It appears that female gender, previous PEP, previous pancreatitis, endoscopic sphincterotomy, precut
sphincterotomy, Sphincter of Oddi dysfunction, and non-prophylactic pancreatic duct stent are the risk factors for
post-ERCP pancreatitis.
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Since endoscopic retrograde cholangiopancreatography
(ERCP) was first introduced in 1968, it has been per-
formed as a diagnostic and therapeutic procedure for va-
rious biliary and pancreatic diseases. The role of ERCP
changed from a diagnostic modality to a therapeutic pro-
cedure after the introduction of recent developments in
magnetic resonance cholangiopancreatography (MRCP)
[1]. Post-ERCP pancreatitis (PEP) is the most common
and severe complication associated with diagnostic and
therapeutic ERCP [2-4]. A small percentage of patients* Correspondence: ximowang12@163.com
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reproduction in any medium, provided the ormay develop severe pancreatitis resulting in a prolonged
hospitalization, intensive care unit admission and utili-
zation of major hospital resources; these patients have a
significant morbidity and mortality [5]. The incidence of
PEP reached up to 3.5% in a systematic review of 21 cli-
nical studies [6]. While the technology and equipment of
ERCP continue to improve, how to reduc the occurrence
of PEP is still a serious clinical problem. It is useful to
identify exactly which conditions are related to this com-
plication, in order to avoid PEP in patients in whom pro-
tective endoscopic or pharmacological measures should
be considered. There is still controversy concerning the
risk factors related to PEP. The aim of the present study
was to perform a systematic review of a series of cases oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Description of the 13 included studies
Study Year Number Methods Incidence of PEP The rates of therapeutic procedures
Andriulli (9) 2002 579 RCT, multicenter, paralled group 8.64% Nr
Vandervoort (17) 2002 1,223 Single center, prospective analysis 7.20% 54.7%
Perney (13) 2003 173 Single center, retrospective analysis 17.92% Nr
Andriulli (10) 2004 1,127 RCT, multicenter, paralled group 5.59% Nr
Xia (12) 2004 380 Single center, retrospective analysis 4.47% 73.7%
Cheng (11) 2006 1,088 RCT, multicenter, paralled group 15.44% 51.9%
Tsuyuguchi (16) 2007 184 Single center, prospective analysis 1.09% 79.9%
Cotton (3) 2009 11,497 Single center, retrospective analysis 2.64% Nr
Matsubayashi (14) 2009 740 Single center, retrospective analysis 3.92% Nr
Wilox (18) 2010 3,499 Single center, prospective analysis 3.15% Nr
Testoni (15) 2010 3,635 Multicenter, prospective analysis 3.77% 96.6%
Zhou (19) 2011 7,168 Single center, retrospective analysis 3.70% NR
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plication which have been mentioned in the literature.
Methods
Identification of trials
Inclusion criteria were as follows [7]: 1) primary clinical
data about multivariate analysis of risk factors for post-
ERCP pancreatitis in the past ten years; 2) criterion in
determining the diagnosis of post-ERCP pancreatitis:
there was at least a three-fold increase in serum amylase
concentration occurring 24 hours after an ERCP, accom-
panied with obvious abdominal pain; and 3) the lite-
rature data were reliable, and the full text could be
obtained.
Exclusion criteria were as follows: 1) retrospective ana-
lysis contained less than 100 cases (the proficiency of
surgeons has a great impact on the results in clinical re-
search with a small sample size); 2) the article types were
either review or case report; 3) there were only OR
values and 95% CI instead of original data in the articles;
4) duplication of results; and 5) studies with less infor-
mation or unknown data description.Figure 1 The effect of female/male gender.Data search strategy
To obtain relevant clinical studies in English and Chinese,
a systematic literature search with predefined search terms
was carried out in MEDLINE, Elsevier and Springer links.
or articles published between 2002 and 2012. The prede-
fined search terms were ‘ERCP (endoscopic retrograde
cholangiopancreatography)’, ‘pancreatitis’, and ‘risk factors’.
The reference lists of all pertinent reviews and articles
were checked to identify additional studies not found in
the computerized database search.
Data extraction and quality assessment
Two authors independently read the abstracts of re-
trieved articles and, subsequently, full-text articles to
identify whether the data were suitable for the syste-
matic review on the basis of specified inclusion and ex-
clusion criteria. Discrepancies in selection were resolved
by discussion.
The Jadad scale [8] was used to grade the methodo-
logical quality of the trials included. The quality scale
ranges from 0 to 5 points, with two or less indicating
low quality and three or more indicating high quality.
Figure 2 The effect of previous PEP.
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To obtain a global measure of the comparative data,
meta-analytical techniques based on The Cochrane Col-
laboration’s Review Manager (RevMan version 4.2) were
used. The estimation of count data is expressed, in the
case of dichotomous variables, as an odds ratio (OR)
(with a 95% confidence interval, 95% CI). P <0.05 was
deemed statistically significant difference.
Results
Description of studies
We reviewed 451 articles that met our search criteria.
After rigorous screening of their full text, 12 of them
satisfied the study inclusion criteria and were included
(Table 1) [3,9-19].
Results of risk factor evaluation
In total, there were 32,381 post-ERCP patients involved
in this review, and 1,309 of them suffered PEP. The inci-
dence of PEP was 4.04%. The following were considered
as risk factors and related information was extracted and
analyzed: sex, history of previous PEP, history of pre-
vious pancreatitis, endoscopic sphincterotomy (EST),
precut sphincterotomy, Sphincter of Oddi Dysfunction
(SOD) and pancreatic duct stenting.
Participants
Eleven studies reported the influence of gender on PEP.
The incidence of PEP in female patients was 4.47%,
compared with 3.22% in male patients. The risk of theFigure 3 The effect of previous pancreatitis.occurrence of PEP in women was 50% more than that
of men, and the difference was statistically significant
(P <0.01). The results of the systematic review are shown
in Figure 1.
Previous PEP
Six studies reported patients with previous PEP. The in-
cidence of PEP in these patients was 17.82%, compared
with 5.03% in control patients. There was a 2.23 times
increased incidence for patients with previous PEP, and
the difference was statistically significant (P < .01). The
results of the systematic review are shown in Figure 2.
Previous pancreatitis
Eight studies reported patients who had a history of
previous pancreatitis. The incidence of PEP in these
patients was 5.46%, compared with 3.12% in control pa-
tients. The risk of the occurrence of PEP is increased
one-fold, and the difference was statistically significant
(P <0.01). The results of the systematic review are shown
in Figure 3.
Endoscopic sphincterotomy (EST)
Eight studies reported patients who underwent an endo-
scopic sphincterotomy. The incidence of PEP in these
patients was 7.09%, compared with 5.50% in control pa-
tients. The risk of the occurrence of PEP in patients with
EST increased by 42%, and the difference was statisti-
cally significant (P <0.01). The results of the systematic
review are shown in Figure 4.
Figure 4 The effect of endoscopic sphincterotomy.
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Nine studies reported patients operated on using the
precut technique. The incidence of PEP in these patients
was 9.64%, compared with 4.93% in control patients.
There was a 1.11 times increased incidence with the pre-
cut technique, and the difference was statistically signi-
ficant (P <0.01). The results of the systematic review are
shown in Figure 5.Sphincter of Oddi dysfunction
Nine studies reported patients with SOD. The incidence
of PEP in these patients was 9.74%, compared with 3.11%
in control patients. There was a 3.37 times increased inci-
dence for SOD, and the difference was statistically signi-
ficant (P <0.01). The results of the systematic review are
shown in Figure 6.Non-prophylactic pancreatic duct stent
Three studies reported patients who underwent pancre-
atic duct stenting. The incidence of PEP in these patients
was 10.21%, compared with 4.12% in control patients.
There was a 1.1 times increased incidence for pancreatic
duct stenting, and the difference was statistically signifi-
cant (P <0.01). The results of the systematic review are
shown in Figure 7.Figure 5 The effect of precut sphincterotomy.Discussion
ERCP is the procedure of choice for treating biliary tract
and pancreatic diseases. While the technology and equip-
ment of ERCP continue to improve, postoperative compli-
cations cannot be completely avoided due to the invasive
form of this surgery. PEP was the most serious and com-
mon complication following ERCP. How to determine risk
factors for PEP is an all too urgent clinical issue because it
is essential for identifying patients at high risk and sub-
sequently choosing other suitable treatment, such as
magnetic resonance cholangiography, endoscopic ultra-
sonography, percutaneous transhepatic biliary drainage,
and so on.
After rigorous screening, 13 clinical trials which pro-
vided data about risk factors for PEP were included in this
systematic review. The results suggest that female gender,
previous PEP, previous pancreatitis, precut sphincterot-
omy, SOD and so on were all risk factors for PEP.
It is difficult to demonstrate whether female gender is
an independent risk factor. The increased incidence of
PEP in women would probably be because SOD affects
women more frequently than men [12].
EST s a common and essential procedure in thera-
peutic ERCP. Akashi et al. [20] reported that the edema
in surrounding tissues was induced because of the sensi-
tivity of the pancreatic duct to thermal damage caused
Figure 6 The effect of Sphincter of Oddi dysfunction.
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porarily blocked, all of which caused the occurrence of
PEP. However, in many studies [21-24], EST was not
considered to be a risk factor for PEP. Theoretically,
EST can reduce the tension at the orifice of the pan-
creatic duct. The incidence of post-EST pancreatitis is
largely dependent upon the skill of the endoscopist, in
addition to factors related to the host. Endoscopists
must aim to improve their technique and fully utilize
their abilities under an adequate guidance system [25].
Precut sphincterotomy may cause edema of the duo-
denal papilla, a poor discharge of pancreatic juice,and in-
duce post-ERCP acute pancreatitis [26]. In this study,
the incidence of PEP in patients after precut sphincterot-
omy was approximately twice that in patients without
precut sphincterotomy. Some studies showed that the
incidence of complications after precut sphincterotomy
was closed is related to the precut position, and that
there is a minimal risk for postoperative complications
when the precut occurs on the top of the duodenal
papilla [19]. Thus, the top of the papilla is a better
choice for precut sphincterotomy. Pre-cut techniques
are mostly used after conventional methods of biliary
cannulation have failed or, in a few centers, as a prefe-
rential technique for performing biliary and pancreatic
sphincterotomy over a pancreatic stent in patients with
SOD [27]. Therefore, difficult cannulation is a risk factor
for PEP. Martin et al. [28] reported that the incidence of
PEP after precut sphincterotomy is highly related to the
technique used by the endoscopists. Further research isFigure 7 The effect of pancreatic duct stenting.necessary to access the relationship between pre-cut
techniques and PEP.
SOD is a benign noncalculous obstructive disorder oc-
curring at the level of the Sphincter of Oddi which causes
pancreaticobiliary-type pain. Criteria for diagnosing SOD
have been established by the Rome III conference [29]. Pa-
tients suspected of having SOD should have episodes of
abdominal pain that is located in the epigastrium and
right upper quadrant and is associated with the following
features: 1) ≥30 minutes in duration, 2) recurrent symp-
toms occurring at variable intervals (not daily), 3) occur-
ring on one or more occasions in the last 12 months, 4)
pain that builds up to a steady level, 5) pain that is mode-
rate to severe enough to interrupt a patient's daily acti-
vities, and 6) no evidence of structural abnormalities to
explain the symptoms. SODis more common in women.
SOD is considered a definite independent risk factor for
PEP in some studies [18-20]. The placement of a pan-
creatic stent or nasal pancreatic drainage would signifi-
cantly reduce the incidence of PEP in patients with SOD.
Recently, research supported pancreatic-stent place-
ment as an effective intervention for the prevention of
PEP in high-risk patients [30]. However, placement of
a pancreatic-stent is a risk factor for PEP in this syste-
matic review. This is mainly because the pancreatic-
stent placement was for therapeutic purposes other than
prevention in the included studies. Patients with pan-
creatic diseases, such as obstruction of the pancreatic
duct and pancreatolithiasis, needed drainage of pancre-
atic juice via a pancreatic stent.
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[7], which showed that the risk factors for PEP may
change according to the development of instruments
and technologies. Therefore we chose more potential
risk factors in this systematic review of clinical trials in
the past ten years, which would give a more objective re-
sponse of risk factors for PEP.
From this systematic review a three-pronged approach
could be advised to prevent PEP: 1) Preoperative exa-
mination is needed to determine patients who are suit-
able to undergo surgery; 2) Surgeons need more suitable
training to improve their surgical proficiency; and 3)
Various preoperative, intraoperative and postoperative
preventive practices should be used, such as the use of
somatostatin analogs [31] and pancreatic stents [30],
could minimize the incidence of PEP and reduce harm
to patients.
The limited information in some studies, the absence
of some variables, the fact that many risk factors had
already been identified in previous studies, and the fact
that many were reported in a way that precluded com-
parison across studies may limit the usefulness of our re-
sults. However, the large number of cases considered for
analysis of the single risk factors for pancreatitis sub-
stantiate the findings.
Several limitations of the present study need to be
considered. First, it is difficult to perform randomized
controlled trials (RCTs) because of the low incidence of
PEP, so both prospective and retrospective studies were
selected for analysis, which produces some bias in the
analysis. Secondly, there was significant heterogeneity
among these studies. The heterogeneity might be ex-
plained by the study design, study quality, patients’ cha-
racteristics, and the diverse technical specifications.Conclusions
Despite these limitations, our findings have important
implications concerning the risk factors for PEP, and we
conclude that female gender, previous PEP, previous
pancreatitis, endoscopic sphincterotomy, precut sphinc-
terotomy, SOD and non-prophylactic pancreatic duct
stent are the risk factors for post-ERCP pancreatitis.
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